Lv4
460 积分 2022-09-14 加入
Final Analysis of the Phase 4 KEYNOTE-B10 Study: First-Line (1L) Pembrolizumab (pembro) + Carboplatin (carbo) + Paclitaxel (pacli) for Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)
1个月前
已关闭
Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up from the randomized phase III KEYNOTE-048 study
3个月前
已完结
Finotonlimab with chemotherapy in recurrent or metastatic head and neck cancer: a randomized phase 3 trial
4个月前
已完结
Head and Neck Cancer
6个月前
已完结
Head and Neck Cancer
6个月前
已完结
Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): A comprehensive analysis by tumour site
6个月前
已完结
Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck at a high risk of relapse (GORTEC 2018-01 NIVOPOST-OP): a randomised, open-label, phase 3 trial
7个月前
已完结
Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer
7个月前
已完结
Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer
7个月前
已完结
Criteria for the diagnosis of extranodal extension detected on radiological imaging in head and neck cancer: Head and Neck Cancer International Group consensus recommendations
7个月前
已完结
皖公网安备34019202002308
